MIRA PHARMACEUTICALS, INC. 8-K — AI Bull & Bear Analysis

The amendment to the MIRALOGX agreement transforms Ketamir-2 from a regional candidate into a global platform, fundamentally altering the company's risk-reward profile. While the expanded territorial rights provide a massive increase in the total addressable market, the lack of accompanying financing raises questions about the company's ability to execute on this global vision. Investors must now weigh the potential for exponential value accretion against the immediate need for capital to support international clinical development.